Clinical trials: Pulmonary Tuberculosis, open to volunteers
Tuberculosis, Pulmonary
DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
The goal of this observational study is to investigate whether model-informed precision dosing (MIPD), as a clinical support for early individualised dosing in addition to the national TB care program, can optimise the drug…
- Trial name
- DoseTB (NCT06585358)
- Testing
- MIPD
- Where
- 2 sites in Sweden
- Volunteers
- 30 people
- Sponsor
- Karolinska Institutet
Tuberculosis Diagnosis
Plasma MTB cfDNA Before Bronchoscopy
Tuberculosis (TB) remains a major global health challenge, affecting over 10 million people annually. Hong Kong carries an intermediate TB burden, with ~3,200 new cases reported yearly.
- Trial name
- NCT07230457
- Testing
- Diagnostic Test: Plasma MTB cfDNA assay
- Where
- Hong Kong
- Volunteers
- 600 people
- Sponsor
- Chinese University of Hong Kong
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
PanACEA - STEP2C -01
This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.
- Trial name
- NCT05807399
- Testing
- BTZ-043, Rifampicin, Isoniazid
- Where
- 10 sites in Gabon, Malawi and 4 more
- Volunteers
- 390 people
- Sponsor
- Michael Hoelscher
Pulmonary Tuberculosis, Tuberculosis
ATORvastatin in Pulmonary TUBerculosis
Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally. According to recent estimates from the World Health Organization (WHO), over 10 million new cases and 1.6…
- Conditions
- Pulmonary Tuberculosis, Tuberculosis, Koch's Disease
- Trial name
- ATORTUB (NCT06199921)
- Testing
- Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg
- Where
- 8 sites in Nigeria
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Obafemi Awolowo University Teaching Hospital
Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM)
A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
The treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate.
- Conditions
- Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid
- Trial name
- NCT07191834
- Volunteers
- 60 people
- Sponsor
- Wuhan Pulmonary Hospital
Tuberculosis, Pulmonary Tuberculoses
Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya
Tuberculosis (TB) can be treated; however, the standard 6-month treatment is long and challenging for many patients, and 10-20% still don't recover well by the end of treatment.
- Conditions
- Tuberculosis, Pulmonary Tuberculoses, Mycobacterium Tuberculosis
- Trial name
- NCT07157904
- Where
- 2 sites in Kenya
- Volunteers
- 300 people
- Sponsor
- Nagasaki University
Pulmonary and Extra- Pulmonary Tuberculosis (TB)
Study About Drug Resistance of Mycobacterium Tuberculosis
Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is…
- Trial name
- NCT07169149
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Sohag University
Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
# Brief Summary This study aims to evaluate the early bactericidal activity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible…
- Trial name
- Beams (NCT07129629)
- Testing
- Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA)
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Pulmonary TB
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease…
- Trial name
- RIFAstrat (NCT07118696)
- Testing
- Extra 600mg of Rifampicin
- Volunteers
- 1,000 people
- Sponsor
- Hamilton Health Sciences Corporation
Tuberculosis in Children, Chronic Lung Disease
Paediatric Post-TB Pulmonary Rehab Study
The goal of this clinical trial is to learn if a home-based pulmonary rehabilitation program is feasible and acceptable for children ages 6-15 who have recently completed treatment for pulmonary tuberculosis.
- Conditions
- Tuberculosis in Children, Chronic Lung Disease, Post Tuberculosis
- Trial name
- PPT Rehab (NCT07097961)
- Testing
- Pulmonary Rehabilitation
- Where
- Uganda
- Volunteers
- 40 people
- Sponsor
- University of Iowa
Pulmonary Tuberculosis
Ultra-Short Regimen for Elderly DS-TB
Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent.
- Trial name
- Elderly-USR (NCT07076225)
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Volunteers
- 300 people
- Sponsor
- Shenzhen Third People's Hospital
Mediastinal Lymphadenopathy, Lung Cancer
Mediastinal EBUS Cryobiopsy Study In Sweden
This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other.
- Conditions
- Mediastinal Lymphadenopathy, Lung Cancer, Sarcoidosis, Lymphoma
- Trial name
- MECRIS (NCT06347939)
- Testing
- Mediastinal lymph nodes cryobiopsies
- Where
- 2 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
Post Pulmonary Tuberculosis, Post-Tuberculous Bronchiectasis
The Feasibility and Acceptability of a Post-tuberculosis Lung Disease Diagnostic Algorithm in Uganda.
The goal of this clinical trial is to determine whether a structured diagnostic algorithm improves the identification and referral of people with post-tuberculosis lung disease (PTLD) in primary healthcare facilities in Uganda.
- Trial name
- IMPULSE (NCT07067528)
- Testing
- A novel PTLD clinical diagnostic algorithm
- Where
- Uganda
- Volunteers
- 80 people
- Sponsor
- Mbarara University of Science and Technology
Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
This is a multicenter, randomized, double-blind, active-controlled Phase III study to evaluate the efficacy and safety of Sudapyridine (WX-081) combined with a background regimen (BR) in patients with rifampicin-resistant…
- Trial name
- WISH (NCT05824871)
- Testing
- Sudapyridine, Bedaquiline
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Tuberculosis, Pulmonary
ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin…
- Trial name
- NCT06714513
- Testing
- QTP101
- Where
- 4 sites in South Korea
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
COPD, Interstitial Pneumonia
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
This study analyzes patients who underwent lung transplantation at the First Affiliated Hospital of Zhejiang University from 2017 to 2024, focusing on anesthesia's impact on post-op results.
- Conditions
- COPD, Interstitial Pneumonia, Bronchiectasis, Respiratory Failure
- Trial name
- NCT06922916
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Zhejiang University
Tuberculosis, Pulmonary
Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline
The goal of this clinical trial is to assess the efficacy(effectiveness) of doxycycline, a potent inhibitor of matrix metalloproteinase (lung collagenase) activity in prevention of Tuberculosis associated lung fibrosis and…
- Trial name
- TALF-TB (NCT06477185)
- Testing
- Doxycycline
- Where
- 2 sites in Uganda
- Volunteers
- 200 people
- Sponsor
- Makerere University
Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent…
- Conditions
- Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs
- Trial name
- Tri-Do-Re (NCT04260477)
- Testing
- 6EH³R³Z, 6EHRZ
- Where
- Niger
- Volunteers
- 370 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Respiratory Disease, Substance-Related Disorders
Development of the Drug and Alcohol Respiratory Health Test
The goal of this study is to develop a brief Drug and Alcohol Respiratory Health Test (DARHT) and offer it for routine use in clinical assessment and medical reviews
- Conditions
- Respiratory Disease, Substance-Related Disorders, COPD, Asthma
- Trial name
- DARHT (NCT06921278)
- Where
- United Kingdom
- Volunteers
- 260 people
- Sponsor
- King's College London
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health